Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$13.00 USD
+0.71 (5.78%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $12.89 -0.11 (-0.85%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Cash flow Statements
Fiscal Year End for Cidara Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -29.80 | -42.47 | -72.11 | -41.09 |
Depreciation/Amortization & Depletion | NA | 1.23 | -1.23 | 0.29 | 0.34 |
Net Change from Assets/Liabilities | NA | -3.43 | 14.44 | 13.36 | 7.49 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 3.53 | 4.03 | 4.05 | 4.74 |
Net Cash From Operating Activities | NA | -28.47 | -25.23 | -54.41 | -28.53 |
Property & Equipment | NA | -0.12 | -0.04 | -0.19 | -0.04 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.12 | -0.04 | -0.19 | -0.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.64 | 12.49 | 40.24 | 14.30 |
Issuance (Repayment) of Debt | NA | -2.59 | -4.44 | -2.96 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 36.55 | 0.00 | -0.03 |
Net Cash from Financing Activities | NA | -0.95 | 44.60 | 37.28 | 14.27 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -29.54 | 19.32 | -17.32 | -14.29 |
Cash at Beginning of Period | NA | 62.27 | 42.95 | 60.27 | 74.56 |
Cash at End of Period | NA | 32.73 | 62.27 | 42.95 | 60.27 |
Diluted Net EPS | NA | -0.43 | -0.81 | -1.80 | -1.41 |
Fiscal Year End for Cidara Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | -17.32 | -9.15 | 3.21 |
Depreciation/Amortization & Depletion | NA | NA | 1.05 | 0.10 | 0.80 |
Net Change from Assets/Liabilities | NA | NA | 4.33 | -1.12 | -15.54 |
Net Cash from Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | NA | 2.23 | 2.10 | 0.64 |
Net Cash From Operating Activities | NA | NA | -9.71 | -8.08 | -10.90 |
Property & Equipment | NA | NA | -0.33 | -0.20 | -0.09 |
Acquisition/ Disposition of Subsidiaries | NA | NA | 0.00 | 0.00 | 0.00 |
Investments | NA | NA | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | NA | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | NA | -0.33 | -0.20 | -0.09 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | 25.98 | 25.98 | 26.24 |
Issuance (Repayment) of Debt | NA | NA | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | NA | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | NA | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | NA | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | NA | 25.98 | 25.98 | 26.24 |
Effect of Exchange Rate Changes | NA | NA | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | NA | 15.94 | 17.70 | 15.25 |
Cash at Beginning of Period | NA | NA | 32.73 | 32.73 | 32.73 |
Cash at End of Period | NA | NA | 48.67 | 50.43 | 47.98 |
Diluted Net EPS | NA | NA | -0.09 | -0.14 | 0.03 |